VPD-737 for Treatment of Chronic Pruritus

NCT01951274 ↗

Phase 2 Completed 257 enrolled Vyne Therapeutics Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments

Timeline

Start: 2013-10-15
Primary completion: 2014-12-02
Completion: 2014-12-02

Outcome

Met primary endpoint

paper larger with the 1- and 5-mg doses of serlopitant (P = .022 and P = .013, respectively) than with placebo at week 6. PMID 29462657 ↗

Publications

Yosipovitch G, Stander S, Kerby MB, Larrick JW, Perlman AJ, Schnipper EF, Zhang X, Tang JY, Luger T, Steinhoff M. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol. 2018 May;78(5):882-891.e10. doi: 10.1016/j.jaad.2018.02.030. Epub 2018 Feb 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Serlopitant	Small molecule	0.25 mg	Oral
Subject	Serlopitant	Small molecule	1 mg	Oral
Subject	Serlopitant	Small molecule	5 mg	Oral

Indications

No indication recorded.